US20040167612A1 - Process for producing stents and corresponding stents - Google Patents
Process for producing stents and corresponding stents Download PDFInfo
- Publication number
- US20040167612A1 US20040167612A1 US10/782,412 US78241204A US2004167612A1 US 20040167612 A1 US20040167612 A1 US 20040167612A1 US 78241204 A US78241204 A US 78241204A US 2004167612 A1 US2004167612 A1 US 2004167612A1
- Authority
- US
- United States
- Prior art keywords
- stent
- active substance
- process according
- regions
- mask
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 90
- 239000013543 active substance Substances 0.000 claims abstract description 81
- 239000000843 powder Substances 0.000 claims abstract description 29
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims abstract description 23
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims abstract description 17
- 238000000151 deposition Methods 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims description 24
- 238000000576 coating method Methods 0.000 claims description 20
- 239000011248 coating agent Substances 0.000 claims description 16
- 238000012546 transfer Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 239000003575 carbonaceous material Substances 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000007598 dipping method Methods 0.000 claims description 6
- 238000007786 electrostatic charging Methods 0.000 claims description 6
- 238000007600 charging Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 230000008602 contraction Effects 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 description 51
- 229940079593 drug Drugs 0.000 description 50
- 239000000126 substance Substances 0.000 description 41
- 238000004140 cleaning Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 230000006641 stabilisation Effects 0.000 description 10
- 238000011105 stabilization Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000002513 implantation Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000037803 restenosis Diseases 0.000 description 7
- 238000005096 rolling process Methods 0.000 description 7
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- 108010092160 Dactinomycin Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930012538 Paclitaxel Natural products 0.000 description 3
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Natural products C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229960000640 dactinomycin Drugs 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229960001592 paclitaxel Drugs 0.000 description 3
- 239000002831 pharmacologic agent Substances 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- XFILPEOLDIKJHX-QYZOEREBSA-N batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 2
- 229950001858 batimastat Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- -1 ethanol Chemical compound 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- ZBIAKUMOEKILTF-UHFFFAOYSA-N 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl]-N-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1CCN(CCCC(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 ZBIAKUMOEKILTF-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical compound CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- NMKSAYKQLCHXDK-UHFFFAOYSA-N 3,3-diphenyl-N-(1-phenylethyl)-1-propanamine Chemical compound C=1C=CC=CC=1C(C)NCCC(C=1C=CC=CC=1)C1=CC=CC=C1 NMKSAYKQLCHXDK-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- VKPYUUBEDXIQIB-QBPWRKFFSA-N Ciprostene Chemical compound C1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@]21C VKPYUUBEDXIQIB-QBPWRKFFSA-N 0.000 description 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000002149 Elafin Human genes 0.000 description 1
- 108010015972 Elafin Proteins 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960003099 amcinonide Drugs 0.000 description 1
- ILKJAFIWWBXGDU-MOGDOJJUSA-N amcinonide Chemical compound O([C@@]1([C@H](O2)C[C@@H]3[C@@]1(C[C@H](O)[C@]1(F)[C@@]4(C)C=CC(=O)C=C4CC[C@H]13)C)C(=O)COC(=O)C)C12CCCC1 ILKJAFIWWBXGDU-MOGDOJJUSA-N 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- 229940051880 analgesics and antipyretics pyrazolones Drugs 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 150000003975 aryl alkyl amines Chemical class 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 1
- 229950010231 brequinar Drugs 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 150000004652 butanoic acids Chemical class 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DERZBLKQOCDDDZ-JLHYYAGUSA-N cinnarizine Chemical compound C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)CCN1C\C=C\C1=CC=CC=C1 DERZBLKQOCDDDZ-JLHYYAGUSA-N 0.000 description 1
- 229960000876 cinnarizine Drugs 0.000 description 1
- 229950009522 ciprostene Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002842 clobetasol Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004299 clocortolone Drugs 0.000 description 1
- YMTMADLUXIRMGX-RFPWEZLHSA-N clocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O YMTMADLUXIRMGX-RFPWEZLHSA-N 0.000 description 1
- 229960005537 combretastatin A-4 Drugs 0.000 description 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 1
- 238000003851 corona treatment Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 229960002602 fendiline Drugs 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004511 fludroxycortide Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- NZLHIVUUYZXTDR-OFSAWIQQSA-N iu18ho8u80 Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC(C)=O)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)C=3C=CC=CC=3)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC(=O)CCCCC)C(=O)C1=CC=CC=C1 NZLHIVUUYZXTDR-OFSAWIQQSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960001941 lidoflazine Drugs 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- XLFWDASMENKTKL-UHFFFAOYSA-N molsidomine Chemical compound O1C(N=C([O-])OCC)=C[N+](N2CCOCC2)=N1 XLFWDASMENKTKL-UHFFFAOYSA-N 0.000 description 1
- 229960004027 molsidomine Drugs 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229960002858 paramethasone Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N retinoic acid group Chemical class C\C(=C/C(=O)O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- IXTCZMJQGGONPY-XJAYAHQCSA-N rofleponide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3O[C@@H](CCC)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O IXTCZMJQGGONPY-XJAYAHQCSA-N 0.000 description 1
- 229950004432 rofleponide Drugs 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 229940072272 sandostatin Drugs 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229940035636 somatostatin and analogues Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 229960001017 tolmetin Drugs 0.000 description 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/084—Carbon; Graphite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Definitions
- the present invention relates to stents.
- Stents are expandable endoprostheses that can be implanted in a lumen of the human body or animal body, such as a blood vessel, for re-establishing and/or maintaining the patency thereof.
- Stents are usually configured as devices of a tubular shape which operate so as to maintain open a segment of a blood vessel or of another anatomic lumen.
- Stents have become widely used over the last few years for the treatment of stenosis of an arteriosclerotic nature in blood vessels such as coronary arteries. Stents are now being used in other regions of the body such as the peripheral regions.
- EP 0 850 604 A2 describes the possibility of providing the stent with a sculpture that comprises, for instance, recesses that may receive one or more drugs that are useful in the prevention or treatment of restenosis and/or other substances that are expedient for ensuring proper use of the stent (adhesion, mode of release, kinetics, etc.).
- the surface sculptures are characterized both by the outline and the surface of the recess, and by the depth profile.
- the recesses may be cavities having circular or else ovoidal or again elongated openings. Alternatively, they can assume the form of an appropriate alternation of cavities with openings of different types according to the needs of release.
- the depth profile may be U-shaped or V-shaped, or shaped like a vessel with or without a surface part completely dedicated to the reception of the substances in question referred to above.
- the surface part may assume the appearance of a sort of continuous layer on just the outer surface of the stent.
- the material to be loaded on the stent may consist of just one drug, of a pair of drugs, or of an ensemble of drugs with similar, synergetic, or different actions.
- the stent can serve as a vehicle for substances having the function of adjuvant of pharmacologically active substances, such as polymers or excipients of various natures. The function may be of stabilization of the active substance or active substances, or else be aimed at regulating the kinetics of release (deceleration or acceleration of release).
- the polymers/excipients can be mixed with the drug or drugs or else are in separate layers with respect to the pharmacologically active substances.
- a recess in the stent could contain a sort of bioerodible-polymer plug or the material on the stent could have a stratified structure with successive layers of drug and polymer.
- the character of activity of the substances loaded on the stent may include substances that are of a radioactive nature.
- rapamycin sirolimus
- FK506 tacrolimus
- the problems linked to the use of drugs on the stent are not moreover limited to the choice alone, i.e., to the identification of the substance or substances used, but involve various other aspects. Among these further aspects are: (i) the physical form of the substances to be loaded; (ii) the technique of loading of the material; (iii) the technique of cleaning of the excess material deposited; and (iv) the stabilization of the material itself.
- the techniques of loading should take into account the nature (i.e., the physical form) of the substance or substances loaded on the stent.
- Some techniques of loading of a known type basically operate in an indirect way in so far as they substantially envisage the formation of a coating on the stent, typically one of polymeric material (for example polymers of methacrylate, polyurethane, PTFE, hydrogel or hydrogel/polyurethane mixture, especially PTFE), to which the drug to be applied on the stent is linked and/or in which it is dissolved before application of the coating, subsequently designed to be stabilized by polymerization.
- Other techniques substantially envisage, instead, starting from agents in liquid form or low-viscosity solutions or dispersions. This method is used because in the majority of cases considered because the drugs in question are available in the market in the form of a powder (of different grain size).
- the simplest solution envisages loading the stent by dipping it in a carrier, typically a liquid, in which is dissolved, suspended or anyway present the substance or substances to be loaded on the stent.
- a carrier typically a liquid
- This technique which may possibly be conducted in vacuum conditions, is referred to in the art as “dipping”.
- dipping the document WO 02/065947 A2 describes a solution in which the stent is brought into contact with a solution of FK506 in aqueous or organic solvent (typically in an alcohol, such as ethanol, in a concentration of 3.3 mg of FK506 in 1 ml of ethanol). This takes place, for example, by dripping, spraying or dipping, preferably in vacuum conditions.
- the stent is then dried, preferably enough to remove the solvent.
- the drug coating operation preferably is then repeated from one to five times. Subsequently, the stent is possibly washed one or more times with water or isotonic saline solution, and may then possibly be dried.
- the purpose of the present invention is to overcome the drawbacks pointed out above, paying particular attention to its possible use for making stents with associated biologically active substances, i.e., the so-called “bioactive stents”.
- the above mode of use regards in particular the possible presence on the stent of at least one drug which may perform a restenosis-antagonist function, such as for example FK506.
- the above purpose is achieved thanks to a process having the characteristics described below.
- the invention also regards the corresponding stent.
- the invention envisages carrying out the loading operation starting from a powder or from a paste obtained from the powder itself.
- the term “paste” is here understood to indicate any plastic mass having a degree of viscosity such as to ensure that the mass will substantially preserve its shape if exposed only to the force of gravity. This definition is in evident contrast with a liquid or cream, which do not demonstrate these characteristic of preservation of shape. The existence or else absence of this characteristic may be determined in a simple way by depositing on a surface a mass of substance in an amount corresponding to the quantity required for the applications here considered and verifying whether the mass preserves or else modifies its shape as a result of the force of gravity.
- the powder or paste here considered may consist of: (i) a pure drug; (ii) a mixture of two or more drugs in appropriate proportions; and (iii) a mixture of drugs, excipients and/or substances (such as polymers) that contribute to the control of the kinetics of release.
- the drug is FK506, i.e., the macrolide antibiotic FK506 (tacrolimus, [3S-[3R*[AND(1S*,3S*,4S*)],4S*,5R*,-8S*,9E,12R*,14R*, 15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15, 16,17,18,19,24,25,25,26a-hexadecahydro-5,19-dihydroxy- 3-[2 -(4-hydroxy-3-methoxycyclohexyl)-1-methylentenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxa-azacyclotricosin-1,7,20,21(4H,
- Drugs presenting characteristics that are on the whole similar, which can be used in association with, or alternatively to, FK506, are: cyclosporine, leflunomide, mycophenolate, brequinar, rapamycin, everolimus, ABT-574 or other derivatives of rapamycin; PDGF antagonists; paclitaxel or 7 -hexanoyl-taxol; cisplatin; vinblastin; mitoxantrone; combretastatin A4; topotecan; methotrexate; flavopyridol; actinomycin D; rheopro/abciximab or probucol, and drugs capable of mitigating or preventing reactions underlying the process of restenosis, such as: rapamycin, heparin and the like, actinomycin D, batimastat, paclitaxel, resten NG (oligonucleotide), and dexamethasone.
- Drugs that can be advantageously combined with FK506 and/or other drugs with restenosis-antagonist action, or else, in general, drugs that can be loaded on a stent according to the modalities herein described include the following.
- Drugs with anti-inflammatory action such as:
- NSAIDs Non-steroidal anti-inflammatory drugs
- Salicylates Acetylsalicylic acid
- Nitrogenated mustards Cyclophosphamide
- Vinca alkaloids Vinblastine
- Antibiotics Actinomycin D,
- Taxanes Taxol
- Endothelial/angiogenetic growth factors e.g., VEGF or antisense oligonucleotides
- Antisense oligonucleotides e.g., antisense c-myb,
- Arylalkylamines Diltiazem, Verapamyl, Fendiline, Gallopamyl, etc.
- Dihydropyridines Amlodipine, Nicardipine, etc.
- Piperazines Cinnarizine, Lidoflazine, etc.
- Statins simvastatin, fluvastatin, etc.
- Somatostatin and analogues Sandostatin, Angiopeptin, etc.
- Anticoagulants Irudin, Heparin and derivatives
- Antiplatelet agents Ticlopidin, Dipyrimidamol, etc.
- active substance also covers direct derivatives of the active substance, and the active substance also in all the types of salts, enantiomers, racemic forms, bases, or free acids of the active substance, and their mixtures.
- the present invention directs its main attention to the technique (rheology) of application thereof.
- the application in the form of a powder or of a paste formed from the powder manages to reconcile the need for making a selective application (an important factor both for the purposes that it is intended to pursue and for the costs of the substances applied, which are usually rather high), with the need of ensuring the firm retention of the substances applied on the stent.
- the above result has been obtained without complex operations of loading, and avoids the need to make on the stent a coating in which the drug to be applied on the stent is bound and/or dissolved.
- the invention provides a method of obtaining with relative ease selective coatings, i.e., coatings limited to well-confined areas of the stent, and/or of loading a plurality of different agents, while avoiding the difficulties that are intrinsically linked to the simultaneous loading of a number of agents and possible excipients or other substances that may contribute to controlling the kinetics of release.
- the result of the process of loading must be selective, in the sense that it must load only those areas of the stent that actually have to carry the drug or drugs, as well as the possible additives (excipients).
- this result can be achieved also passing through a generalized loading, which initially loads also areas of the stent that are designed to be subsequently cleaned to remove the excess substances loaded.
- the next step is fixation of the drug or drugs, as well as of the additives.
- the purpose of this is to ensure that the substances can be effectively transported by the stent onto an implantation site and not be dispersed elsewhere, in particular during advance towards the implantation site or even before the stent is inserted in the body in which it is to be implanted.
- the operations of stabilization can be conducted in a selective way on the sole parts where the presence of the substances deposited is required or else in a generalized way over the entire stent, at least as regards the outer surface thereof.
- the main methods of loading that can be adopted are: (i) recourse to a non-selective corona effect (electrostatic effect), i.e., coating the entire surface with powder and then cleaning the areas that require cleaning; (ii) recourse to a selective electrostatic process (such as photocopier or laser printer), for example through an intermediate roll that collects the powder only in areas corresponding to the recesses, in which it deposits it subsequently; if they are stents with the entire outer surface porous, selectivity is in general not required, and, in both of the cases so far considered, no specific cleaning operation is called for; (iii) rolling on a bed or mat of powder, with subsequent cleaning; and (iv) rolling on a bed or mat of powder with a mask of a serigraphic type so as to load the recesses alone; no cleaning is required.
- a non-selective corona effect electrostatic effect
- a selective electrostatic process such as photocopier or laser printer
- the main methods of loading usable are: (i) rolling on a bed or mat of paste, with subsequent cleaning; (ii) rolling on a bed or mat of paste with a protective mask (serigraphy); cleaning is not required; and (iii) application with a dispensing nozzle, typically moved by a numerical control machine for fine positioning.
- stabilization gives the content of the cavity a mechanical quality and a degree of adhesion to the recesses themselves adequate for the mechanical stress exerted on the stent in the steps of transportation, storage, procedure, and expansion.
- FIGS. 1 to 3 illustrate, in general terms, the operation of loading of a drug or of another substance in the form of powder or paste on a stent.
- FIGS. 4 to 6 are schematic illustrations of the loading operation performed with an electrostatic process (corona effect) of a non-selective type.
- FIGS. 7 and 8 are schematic illustrations of the loading operation performed with an electrostatic process of a selective type.
- FIGS. 9 to 11 are schematic illustrations of the loading operation performed with a process of rolling on a bed or mat.
- FIG. 12 illustrates the implementation of the loading operation by a device for dispensing a paste.
- a stent 1 substantially corresponding to the stent described in U.S. Pat. No. 6,325,821 B1, the contents of which are hereby incorporated by reference herein.
- a stent consists of a tubular body made of metal material, which may be dilated, starting from a radially contracted condition to a radially expanded condition.
- the body of the stent comprises a plurality of structural elements or struts 10 , which define a structure with openings presenting an on the whole reticular character.
- the structure in question comprises a plurality of annular segments arranged in succession along the longitudinal axis of the stent.
- the segments in question present a serpentine pattern with loop-like parts arranged in opposite sequence, connected together by connection elements (commonly referred to as “links”).
- the serpentine sequences of the successive segments are usually in phase opposition, i.e., with a concavity of each serpentine opposite to a concavity of an adjacent segment.
- the connection elements present a substantially V-shaped pattern with a profile characterized by an alternation of concave portions and convex portions.
- the aforesaid connectors connect the various annular segments of the stent at the “0” points or nodes of the serpentine paths of the segments.
- the stent 1 is represented in cross section, so that in the drawings only the circular trace of the cross section is perceptible, which is defined by a certain number of struts traversed by the cross-sectional plane.
- the stent in question is provided, on its outer surface, with a sculpture formed by a pattern with recesses 12 of the type described in U.S. Pat. No. 6,638,302 B1 or U.S. patent application Publication No. 2003/0028242 A1, the contents of each of which are hereby incorporated by reference herein.
- the recesses 12 can receive within them respective masses 14 of a material comprising an active substance, such as FK 506 and/or any one of the other substances or combinations of substances to which ample reference has been made previously.
- the stent in question is coated, on its outer surface, with a layer of biocompatible carbon material deposited thereon by resorting to the technique described, for example, in U.S. Pat. Nos. 5,084,151, 5,133,845, 5,370,684, 5,387,247, and 5,423,886, the contents of each of which are hereby incorporated by reference herein.
- the presence of the coating of biocompatible carbon material proves advantageous for the purposes of use of the stent, in particular as regards the minimization of the effects resulting from the implantation of the stent.
- the presence of the coating of biocompatible carbon material proves likewise advantageous for the purposes of loading of the stent, which is performed with the processes of an electrostatic type described in greater detail in what follows.
- FIGS. 1 to 3 of the annexed drawings illustrate the technique here described in its more general terms.
- the stent 1 is usually mounted on a support or spindle 16 designed to enable its manipulation (also by means of a mechanical manipulator, which may possibly be automatic) without risks of damage.
- the stent can be treated both in a radially expanded condition, and in a radially contracted condition.
- the treatment in a radially contracted condition is, however, preferred in that it facilitates the operations of manipulation and cleaning. Tests show that the radial contraction of a stent loaded in a radially expanded condition leads to a modest compacting of the substance loaded in the recesses 12 , which acts in a synergetic way with the stabilization of the substance itself.
- FIG. 2 illustrates the operation whereby (according to different modalities, described in greater detail in what follows) the substance M designed to be loaded in the recesses 12 is applied, in the form of a powder or a paste, on the surface of the stent 1 .
- FIG. 2 refers to an operation of application performed in a non-selective way, i.e., ensuring that the substance M not only fills the recesses 12 , but covers instead the surface of the stent 1 in a practically complete way.
- FIG. 3 illustrates the subsequent cleaning operation, in which the substance M in excess is removed.
- the substance M can be removed by using a localized jet of fluid coming from one or more nozzles 17 so as to leave only the specific dose 14 inside the recesses 12 .
- a very fine powder, with a typical grain size of less than 15 micron, of drug FK 506 (tacrolimus) is laid in a thin and level layer inside a tray V.
- the stent 1 is positioned on a support 16 capable of being charged electrostatically, for example as a result of a corona treatment of the type currently performed on the printing rolls of photocopier machines (FIG. 4).
- the support 16 is electrostatically charged, and the support 16 /stent 1 ensemble is made to rotate (FIG. 5) at a distance of a few tenths of a millimeter from the surface of the powder that is in the tray V.
- the drug M is attracted over the entire surface of the support/stent ensemble and adheres in a uniform way to the stent, also filling its cavities 12 .
- the next step is to remove the excess of drug M from the areas other than the recesses 12 .
- the stent 1 still fitted on its support 16 is cleaned by a sequence of jets of cold water and of nitrogen under pressure shot from one or more nozzles 17 appropriately positioned around the stent (FIG. 6).
- the stent 1 is fitted on a nozzle comprising a perforated tube and is impinged upon by a short sequence of jets of cold water, emitted under pressure from inside the stent.
- the jets of water are interspersed with puffs of nitrogen under pressure.
- the remaining residue is removed from the outer surface of the stent thanks to the rubbing of the latter against a second support, e.g., a cylinder with a compliant, i.e., soft surface.
- the stent that has been loaded is subjected to a spray of solvent effective on FK506, such as for example acetonitrile, from a distance of 15 cm, or else exposed to acetonitrile vapors in a chamber for thin-layer chromatography for 5 minutes.
- solvent effective on FK506, such as for example acetonitrile such as for example acetonitrile
- a very fine powder of the drug FK506 (tacrolimus), with the same grain size as in Example 1, is laid in a thin and level layer inside a tray V.
- a roll 18 coated with photosensitive material capable of being charged electrostatically is exposed to a light source 20 capable of activating or de-activating in a selective way (from the standpoint of electrostatic charging) areas of the surface of the photosensitive roll 18 according to a geometry corresponding to the geometry of the recesses 12 (FIG. 7).
- the final result is the presence, on the surface of the roll 18 , of a distribution of electrostatic charges that reproduces the distribution of the recesses 12 on the surface of the stent.
- the roll 18 carries away with it masses 14 of drug M, the distribution and shape of which correspond to those of the recesses 12 (FIG. 8).
- the roll 18 is then used (like an offset roll in a similar printing process) for transferring the masses 14 into the recesses 12 of the stent 1 mounted on the support 16 (this also usually being charged electrostatically) (FIG. 8).
- the drug M is deposited on the stent 1 , which turns in an opposite direction alongside the roll 18 , in areas corresponding to the sculptures or recesses 12 .
- the next step of the process is the fixation of the substance according to the procedure already described previously (acetonitrile vapors in a thin-layer chromatography chamber for 5 minutes).
- Examples 1 and 2 set forth previously can also be implemented using a paste and not a powder.
- the transfer of the substance M onto the electrostatically charged areas of the stent 1 or of the roll 18 usually presupposes an at least marginal contact and not only the close proximity between the substance M and the stent 1 or the roll 18 .
- a mixture of drug FK506 (tacrolimus) with glycerine is prepared by amalgamating the powder of Example 1 with a few drops of glycerine.
- the paste thus obtained, indicated by M, has a viscosity that is hard to determine but can be estimated to have a lower limit of 100,000 to 120,000 cps.
- the paste M is then deposited and spread out over a surface P, such as for example the bottom of a tray (not illustrated), so as to form a uniform bed or mat.
- the support 16 for the stent is mounted so as to be able to rotate with respect to its longitudinal axis and an axis to translate along the tray itself on a track.
- the outer surface of the stent comes into contact with the paste M, and a layer of paste P is deposited on the outer surface of the stent and fills the recesses 12 (FIG. 9).
- the stent is subsequently exposed to vapors of ethyl alcohol in a thin-layer chromatography chamber. Exposure is performed for 5 minutes at 30° C. The stent is then left to dry for 6 hours, dipped for 15 seconds in water, and again left to dry for 24 hours.
- the operation of removal of the fractions of paste M that remain adherent to the regions of the surface of the stent other than the recesses 12 may possibly follow the operation of stabilization, instead of preceding it.
- a mixture of drug FK506 (tacrolimus) and of polycaprolactone in the form of powder (in a ratio of 6:4) is prepared by amalgamating the powder with a few drops of ethyl acetate. Also in this case, the paste thus obtained, designated by M, has a viscosity that is hard to determine but can be estimated to have a lower limit of 100,000 to 120,000 cps.
- the paste M is then deposited and spread out over a surface P, such as for example the bottom of a tray (not illustrated), so as to form a uniform bed or mat.
- a surface P such as for example the bottom of a tray (not illustrated)
- the support 16 for the stent is mounted so as to be able to rotate with respect to its longitudinal axis and translate along the tray itself on a track, applying to the stent a certain pressure in the direction of the bed of paste M.
- a mask 22 consisting of a metal cylinder with slits 24 the geometry of which corresponds to the geometry (number, shape and position) of the sculptures or recesses 12 present on the outer surface of the stent (FIG. 11).
- the diameter of the mask 22 is chosen so that, once fitted on the stent 1 , the mask 22 will adhere perfectly to the outer surface thereof, leaving free only the required recesses 12 .
- the movement of rotation and translation of the support 16 /stent 1 /mask 24 ensemble on the tray containing the paste M enables deposition of a layer of paste M on the outer surface of the mask 24 and in the recesses 12 of the stent 1 that are left free by the openings 24 of the mask 22 .
- the next step is the fixation of the drug-polymer mixture to the surface of the stent 1 /mask 22 ensemble, for example by putting everything in a stove at 65° C. for 15 minutes. Once cooled, the stent 1 is released from the mask 22 and slid out of the support 16 .
- Example 4 lends itself to repetition with different masks and different substances, so as to fill different recesses with different drugs.
- the process of Example 4 seen previously can be conveniently implemented, as follows: (i) applying on the stent 1 a first mask 22 with first openings 24 that leave uncovered first regions or recesses 12 of the stent 1 ; (ii) exposing the stent 1 , with the first mask applied thereto, to the bed of active substance M, so that the active substance M will coat the mask 22 and the first regions 12 left uncovered by the openings 24 of the first mask 22 ; (iii) removing the first mask 22 from the stent 1 , which is covered with the active substance in areas corresponding to the (first) regions or recesses 12 seen previously; (iv) applying on the stent 1 a second mask 22 with second openings 24 , which leave uncovered second regions 12 of the stent (these may coincide at least in part with the regions 12 already coated); (v) exposing the s
- Examples 3 and 4 described previously are suited to being implemented with a bed or mat of substance M in the form of powder and not in the form of paste.
- FIG. 12 refers to the possibility of applying selectively only inside the recesses 12 , respective masses 14 of material in the form of paste. This is achieved by means of a dispensing nozzle 25 which may be brought into a position facing the recesses 12 , then imparting on the recess 12 each time involved and on the nozzle 25 a relative movement that leads the nozzle to “scan” the recess 12 , depositing inside it the substance M.
- This solution may be achieved with a high degree of precision by resorting to a numerical control machine for controlling the relative movement (usually of translation and rotation) of the support 16 that carries the stent 1 and of the dispensing nozzle 25 .
- the final result achieved is the location of the active substance M on the surface of the stent 1 , in a position directly exposed to the outside, even though usually at least slightly set back in the recesses 12 , without the need for providing coatings or sheaths of any sort on the surface of the stent.
- the surface of the stent thus remains free, with the coating of biocompatible carbon material preferably provided thereon, with consequent beneficial effects both in the implantation site of the stent, and in the steps subsequent to implantation.
Abstract
A process for depositing an active substance on selected regions of the surface of a stent, comprising: (i) providing the active substance in at least one form selected from the group consisting of a powder and a paste; and (ii) depositing the active substance on the selected regions of the surface of the stent.
Preferably, the active substance comprises or consists essentially of FK506, such as FK506 in the form of a powder with a grain size smaller than 15 micron or a paste with a base of FK506 with a viscosity not lower than 100,000 to 120,000 cps.
Description
- The present invention relates to stents. Stents are expandable endoprostheses that can be implanted in a lumen of the human body or animal body, such as a blood vessel, for re-establishing and/or maintaining the patency thereof. Stents are usually configured as devices of a tubular shape which operate so as to maintain open a segment of a blood vessel or of another anatomic lumen. Stents have become widely used over the last few years for the treatment of stenosis of an arteriosclerotic nature in blood vessels such as coronary arteries. Stents are now being used in other regions of the body such as the peripheral regions.
- The scientific and technical literature, including the patent literature, regarding stents is quite extensive. For example, the following documents relate to stents: EP0 806 190 A1, EP 0 850 604 A2, EP 0 875 215 A1, EP 0 895 759 A1, EP 0 895 760 A1, EP 1 080 738 A1, EP 1 088 528 A1, EP 1 103 234 A1, EP 1 174 098 A2, EP 1 212 986 A1, and EP 1 277 449 A1.
- The activities of research, development and industrialization of stents were directed, in the early years, principally to the geometrical structure and to the corresponding techniques of fabrication (winding of a wire, cutting from a microtube, use of superelastic materials, etc.). The research activity regarding stents then gradually extended to other specific embodiments, and in particular to the possibility of applying on stents or of associating to stents pharmacological agents. Such pharmacological agents are able to perform a specific activity at the implantation site of the stent. Drugs that have a restenosis-antagonist action are of particular interest.
- For example, EP 0 850 604 A2 describes the possibility of providing the stent with a sculpture that comprises, for instance, recesses that may receive one or more drugs that are useful in the prevention or treatment of restenosis and/or other substances that are expedient for ensuring proper use of the stent (adhesion, mode of release, kinetics, etc.). The surface sculptures are characterized both by the outline and the surface of the recess, and by the depth profile. For example, the recesses may be cavities having circular or else ovoidal or again elongated openings. Alternatively, they can assume the form of an appropriate alternation of cavities with openings of different types according to the needs of release. The depth profile may be U-shaped or V-shaped, or shaped like a vessel with or without a surface part completely dedicated to the reception of the substances in question referred to above. The surface part may assume the appearance of a sort of continuous layer on just the outer surface of the stent.
- In the course of the last few years, extremely extensive activity has been dedicated to developing materials, particularly pharmacological agents, to be loaded on the stent. The material to be loaded on the stent may consist of just one drug, of a pair of drugs, or of an ensemble of drugs with similar, synergetic, or different actions. In addition to pharmacologically active molecules, the stent can serve as a vehicle for substances having the function of adjuvant of pharmacologically active substances, such as polymers or excipients of various natures. The function may be of stabilization of the active substance or active substances, or else be aimed at regulating the kinetics of release (deceleration or acceleration of release). The polymers/excipients can be mixed with the drug or drugs or else are in separate layers with respect to the pharmacologically active substances. For example, a recess in the stent could contain a sort of bioerodible-polymer plug or the material on the stent could have a stratified structure with successive layers of drug and polymer.
- Even though in scientific circles this type of application is not considered at the moment particularly attractive, the character of activity of the substances loaded on the stent may include substances that are of a radioactive nature.
- The scientific and patent literature relating to materials to be loaded on the stent is extremely extensive, as is witnessed, not only by some of the documents already cited previously, but also by documents such as, for example: EP 0 551 182 A1, EP 0 747 069 A2, EP 0 950 386 A2, EP 0 970 711 A2,
EP 1 254 673 A1,EP 1 254 674 A1, WO 01/87368 A1, WO 02/26280 A1, WO 02/26281 A1, WO 02/47739 A2, WO 02/056790 A2 and WO 02/065947 A2, as well as by the literature cited in these documents. These documents and literature, it may be added, by no means exhaust the field. - As regards the choice of drug having restenosis-antagonist function, the drugs known as rapamycin (sirolimus) and FK506 (tacrolimus) have assumed particular importance.
- The problems linked to the use of drugs on the stent are not moreover limited to the choice alone, i.e., to the identification of the substance or substances used, but involve various other aspects. Among these further aspects are: (i) the physical form of the substances to be loaded; (ii) the technique of loading of the material; (iii) the technique of cleaning of the excess material deposited; and (iv) the stabilization of the material itself.
- The techniques of loading should take into account the nature (i.e., the physical form) of the substance or substances loaded on the stent. Some techniques of loading of a known type basically operate in an indirect way in so far as they substantially envisage the formation of a coating on the stent, typically one of polymeric material (for example polymers of methacrylate, polyurethane, PTFE, hydrogel or hydrogel/polyurethane mixture, especially PTFE), to which the drug to be applied on the stent is linked and/or in which it is dissolved before application of the coating, subsequently designed to be stabilized by polymerization. Other techniques substantially envisage, instead, starting from agents in liquid form or low-viscosity solutions or dispersions. This method is used because in the majority of cases considered because the drugs in question are available in the market in the form of a powder (of different grain size).
- The simplest solution envisages loading the stent by dipping it in a carrier, typically a liquid, in which is dissolved, suspended or anyway present the substance or substances to be loaded on the stent. This technique, which may possibly be conducted in vacuum conditions, is referred to in the art as “dipping”. For example, the document WO 02/065947 A2 describes a solution in which the stent is brought into contact with a solution of FK506 in aqueous or organic solvent (typically in an alcohol, such as ethanol, in a concentration of 3.3 mg of FK506 in 1 ml of ethanol). This takes place, for example, by dripping, spraying or dipping, preferably in vacuum conditions. The stent is then dried, preferably enough to remove the solvent. The drug coating operation preferably is then repeated from one to five times. Subsequently, the stent is possibly washed one or more times with water or isotonic saline solution, and may then possibly be dried.
- The known methods described above, albeit satisfactory, come up against a wide range of drawbacks. Among these are: (i) the complexity of the operation of loading; (ii) the need, in the case where a coating is made on the stent, in which the drug to be applied on the stent is bound and/or dissolved, to take into account the characteristics of the coating and the possible subsequent elimination thereof; (iii) the difficulty of obtaining selective coatings, i.e., ones limited to well-confined areas of the stent; (iv) the difficulty of loading, with a limited number of steps, a plurality of different agents; and (v) the difficulties that are intrinsically linked to the simultaneous loading of a number of agents and possible excipients or other substances that may contribute to the control of the kinetics of release.
- The purpose of the present invention is to overcome the drawbacks pointed out above, paying particular attention to its possible use for making stents with associated biologically active substances, i.e., the so-called “bioactive stents”. The above mode of use regards in particular the possible presence on the stent of at least one drug which may perform a restenosis-antagonist function, such as for example FK506. According to the present invention, the above purpose is achieved thanks to a process having the characteristics described below. The invention also regards the corresponding stent.
- In summary, the invention envisages carrying out the loading operation starting from a powder or from a paste obtained from the powder itself. It will be appreciated that the term “paste” is here understood to indicate any plastic mass having a degree of viscosity such as to ensure that the mass will substantially preserve its shape if exposed only to the force of gravity. This definition is in evident contrast with a liquid or cream, which do not demonstrate these characteristic of preservation of shape. The existence or else absence of this characteristic may be determined in a simple way by depositing on a surface a mass of substance in an amount corresponding to the quantity required for the applications here considered and verifying whether the mass preserves or else modifies its shape as a result of the force of gravity.
- The powder or paste here considered may consist of: (i) a pure drug; (ii) a mixture of two or more drugs in appropriate proportions; and (iii) a mixture of drugs, excipients and/or substances (such as polymers) that contribute to the control of the kinetics of release.
- Preferably, the drug is FK506, i.e., the macrolide antibiotic FK506 (tacrolimus, [3S-[3R*[AND(1S*,3S*,4S*)],4S*,5R*,-8S*,9E,12R*,14R*, 15S*,16R*,18S*,19S*,26aR*]]-5,6,8,11,12,13,14,15, 16,17,18,19,24,25,25,26a-hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylentenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxa-azacyclotricosin-1,7,20,21(4H,23H)-tetrone; Merck index No. 9000). This drug is an active substance originally developed for the medicine of transplants and the immunosuppressive action of which extends evidently also to the restenosis-antagonist mechanism.
- Drugs presenting characteristics that are on the whole similar, which can be used in association with, or alternatively to, FK506, are: cyclosporine, leflunomide, mycophenolate, brequinar, rapamycin, everolimus, ABT-574 or other derivatives of rapamycin; PDGF antagonists; paclitaxel or7-hexanoyl-taxol; cisplatin; vinblastin; mitoxantrone; combretastatin A4; topotecan; methotrexate; flavopyridol; actinomycin D; rheopro/abciximab or probucol, and drugs capable of mitigating or preventing reactions underlying the process of restenosis, such as: rapamycin, heparin and the like, actinomycin D, batimastat, paclitaxel, resten NG (oligonucleotide), and dexamethasone.
- Drugs that can be advantageously combined with FK506 and/or other drugs with restenosis-antagonist action, or else, in general, drugs that can be loaded on a stent according to the modalities herein described include the following.
- Drugs with anti-inflammatory action, such as:
- Corticosteroids,
- Cortisol Betamethasone Fluocinolone,
- Cortisone Dexamethasone Fluocinonide,
- Corticosterol Flunisolide Fluoromethalone,
- Tetrahydrocortisol Alclomethasone Flurandrenolide,
- Prednisone Amcinonide Alcinonide,
- Prednisolone Clobetasol Medrisone,
- Methylprednisolone Clocortolone Momethasone,
- Fluodrocortisone Desonide Rofleponide,
- Triamcinolone Desoxymethasone,
- Paramethasone Diflorasone,
- as well as all the corresponding esters, salts and derivatives.
- Non-steroidal anti-inflammatory drugs (NSAIDs):
- Salicylates: Acetylsalicylic acid,
- Diflunisal,
- Salsalate,
- Pyrazolones: Phenylbutazone,
- Oxyphenbutazone,
- Apazone,
- Indomethacin,
- Sulindac,
- Mephenamic acid and phenamates,
- Tolmetin,
- Derivatives of propionic acid: Ibuprofen,
- Naproxen,
- Fenoprofen,
- Ketoprofen,
- Flurbiprofen,
- Pyroxicam and derivatives,
- Diclofenac and derivatives,
- Etodolac and derivatives,
- Drugs with anti-neoplastic action:
- Alkylating agents:
- Nitrogenated mustards: Cyclophosphamide,
- Melfalan,
- Chlorambucyl,
- Ethylenimin and methylmelamine,
- Alkyl sulphonates,
- Nitrosureas: Carmustin,
- Triazenes,
- Antimetabolites:
- Analogues of Folic acid: Methotrexate
- Analogues of Pyrimidines: Fluorouracyl
- Analogues of Purines and derivatives: Mercaptopurine,
- Thioguadinine.
- Natural Products:
- Vinca alkaloids: Vinblastine,
- Vincristine,
- Epipodofillotoxines: Ethoposide,
- Antibiotics: Actinomycin D,
- Doxorubicin,
- Various:
- Complexes of Platinum: Cisplatinum,
- Mitoxantrone and derivatives,
- Hydroxyurea and derivatives,
- Procarbazine and derivatives,
- Mitotanes,
- Aminoglutetimide,
- Derivatives having a naphthopyranic structure,
- Derivatives of butyric acid,
- Taxanes: Taxol,
- Docetaxel,
- Epotilones,
- Batimastat and analogues,
- Drugs with action promoting processes for repairing the vessel wall,
- Endothelial/angiogenetic growth factors: e.g., VEGF or antisense oligonucleotides,
- Antisense oligonucleotides: e.g., antisense c-myb,
- Prostacyclin and analogues: Ciprostene,
- Dipyridamol,
- Calcium blockers,
- Arylalkylamines: Diltiazem, Verapamyl, Fendiline, Gallopamyl, etc.,
- Dihydropyridines: Amlodipine, Nicardipine, etc.,
- Piperazines: Cinnarizine, Lidoflazine, etc.,
- Colchicines,
- Drugs that act on c-AMP:
- Aminofilline, IBMX (bronchodilators),
- Amrinone (cardiotonic),
- 8-Bromo-c-AMP and c-AMP analogues,
- Drugs that act on the lipid metabolism:
- Statins: simvastatin, fluvastatin, etc.,
- Unsaturated ω-3 fatty acids,
- Somatostatin and analogues: Sandostatin, Angiopeptin, etc.
- Cytocalasines,
- Etretinate and derivatives of retinoic acid,
- Anticoagulants: Irudin, Heparin and derivatives,
- Trapidyl: vasodilator,
- Nitrogen monoxide and its generators: Molsidomin,
- Antiplatelet agents: Ticlopidin, Dipyrimidamol, etc.,
- Agents that can act on the activity of the cell and on the regulation of the
- cell matrix:
- protein (elafin),
- oligonucleotides,
- genes,
- RNA, DNA and fragments,
- RNA, DNA and antisense fragments,
- Monoclonal antibodies.
- For each active substance cited herein, including the active substance FK506, the concept of “active substance” also covers direct derivatives of the active substance, and the active substance also in all the types of salts, enantiomers, racemic forms, bases, or free acids of the active substance, and their mixtures.
- It will moreover be appreciated that, rather than to the identification of the specific substance applied on the stent, the present invention directs its main attention to the technique (rheology) of application thereof. The application in the form of a powder or of a paste formed from the powder manages to reconcile the need for making a selective application (an important factor both for the purposes that it is intended to pursue and for the costs of the substances applied, which are usually rather high), with the need of ensuring the firm retention of the substances applied on the stent.
- The above result has been obtained without complex operations of loading, and avoids the need to make on the stent a coating in which the drug to be applied on the stent is bound and/or dissolved. The invention provides a method of obtaining with relative ease selective coatings, i.e., coatings limited to well-confined areas of the stent, and/or of loading a plurality of different agents, while avoiding the difficulties that are intrinsically linked to the simultaneous loading of a number of agents and possible excipients or other substances that may contribute to controlling the kinetics of release.
- Usually, the result of the process of loading must be selective, in the sense that it must load only those areas of the stent that actually have to carry the drug or drugs, as well as the possible additives (excipients). Of course, this result can be achieved also passing through a generalized loading, which initially loads also areas of the stent that are designed to be subsequently cleaned to remove the excess substances loaded.
- Once the substances chosen have been deposited on the stent (before or after cleaning, according to the operative choices or techniques adopted), the next step is fixation of the drug or drugs, as well as of the additives. The purpose of this is to ensure that the substances can be effectively transported by the stent onto an implantation site and not be dispersed elsewhere, in particular during advance towards the implantation site or even before the stent is inserted in the body in which it is to be implanted. The operations of stabilization can be conducted in a selective way on the sole parts where the presence of the substances deposited is required or else in a generalized way over the entire stent, at least as regards the outer surface thereof.
- In a specific way, in the case where the starting part is a powder, the main methods of loading that can be adopted are: (i) recourse to a non-selective corona effect (electrostatic effect), i.e., coating the entire surface with powder and then cleaning the areas that require cleaning; (ii) recourse to a selective electrostatic process (such as photocopier or laser printer), for example through an intermediate roll that collects the powder only in areas corresponding to the recesses, in which it deposits it subsequently; if they are stents with the entire outer surface porous, selectivity is in general not required, and, in both of the cases so far considered, no specific cleaning operation is called for; (iii) rolling on a bed or mat of powder, with subsequent cleaning; and (iv) rolling on a bed or mat of powder with a mask of a serigraphic type so as to load the recesses alone; no cleaning is required.
- In the case where the starting point is paste, the main methods of loading usable are: (i) rolling on a bed or mat of paste, with subsequent cleaning; (ii) rolling on a bed or mat of paste with a protective mask (serigraphy); cleaning is not required; and (iii) application with a dispensing nozzle, typically moved by a numerical control machine for fine positioning.
- It will moreover be appreciated that whatever the loading procedure adopted, either for paste or for powder, it is then preferable to proceed to a stabilization operation, where by “stabilization” gives the content of the cavity a mechanical quality and a degree of adhesion to the recesses themselves adequate for the mechanical stress exerted on the stent in the steps of transportation, storage, procedure, and expansion.
- To achieve the desired effect of stabilization, it is possible to resort to techniques, such as: (i) exposure to temperature or thermal cycles; (ii) dipping in solvent for controlled lengths of time; (iii) exposure to solvent spray; (iv) exposure to solvent vapors; (v) selective treatment with laser (exposure of the recesses to the laser beam); (vi) selective or integral application of a protective adhesive coating (in the form of a plug for closing the recesses); and (vii) lyophilization.
- The invention will now be described, purely by way of non-limiting example, with reference to the annexed drawings.
- FIGS.1 to 3 illustrate, in general terms, the operation of loading of a drug or of another substance in the form of powder or paste on a stent.
- FIGS.4 to 6 are schematic illustrations of the loading operation performed with an electrostatic process (corona effect) of a non-selective type.
- FIGS. 7 and 8 are schematic illustrations of the loading operation performed with an electrostatic process of a selective type.
- FIGS.9 to 11 are schematic illustrations of the loading operation performed with a process of rolling on a bed or mat.
- FIG. 12 illustrates the implementation of the loading operation by a device for dispensing a paste.
- The present description is provided, purely by way of non-limiting example, with reference to a
stent 1 substantially corresponding to the stent described in U.S. Pat. No. 6,325,821 B1, the contents of which are hereby incorporated by reference herein. Such a stent consists of a tubular body made of metal material, which may be dilated, starting from a radially contracted condition to a radially expanded condition. The body of the stent comprises a plurality of structural elements or struts 10, which define a structure with openings presenting an on the whole reticular character. - In particular, in the solution described in U.S. Pat. No. 6,325,821 B1 the structure in question comprises a plurality of annular segments arranged in succession along the longitudinal axis of the stent. The segments in question present a serpentine pattern with loop-like parts arranged in opposite sequence, connected together by connection elements (commonly referred to as “links”). The serpentine sequences of the successive segments are usually in phase opposition, i.e., with a concavity of each serpentine opposite to a concavity of an adjacent segment. The connection elements present a substantially V-shaped pattern with a profile characterized by an alternation of concave portions and convex portions. The aforesaid connectors connect the various annular segments of the stent at the “0” points or nodes of the serpentine paths of the segments.
- In the view presented in the attached drawings, the
stent 1 is represented in cross section, so that in the drawings only the circular trace of the cross section is perceptible, which is defined by a certain number of struts traversed by the cross-sectional plane. The stent in question is provided, on its outer surface, with a sculpture formed by a pattern withrecesses 12 of the type described in U.S. Pat. No. 6,638,302 B1 or U.S. patent application Publication No. 2003/0028242 A1, the contents of each of which are hereby incorporated by reference herein. Therecesses 12 can receive within themrespective masses 14 of a material comprising an active substance, such as FK 506 and/or any one of the other substances or combinations of substances to which ample reference has been made previously. - In a particularly advantageous way, the stent in question is coated, on its outer surface, with a layer of biocompatible carbon material deposited thereon by resorting to the technique described, for example, in U.S. Pat. Nos. 5,084,151, 5,133,845, 5,370,684, 5,387,247, and 5,423,886, the contents of each of which are hereby incorporated by reference herein. The presence of the coating of biocompatible carbon material proves advantageous for the purposes of use of the stent, in particular as regards the minimization of the effects resulting from the implantation of the stent. The presence of the coating of biocompatible carbon material proves likewise advantageous for the purposes of loading of the stent, which is performed with the processes of an electrostatic type described in greater detail in what follows.
- General Loading Technique
- FIGS.1 to 3 of the annexed drawings illustrate the technique here described in its more general terms. The
stent 1 is usually mounted on a support orspindle 16 designed to enable its manipulation (also by means of a mechanical manipulator, which may possibly be automatic) without risks of damage. The stent can be treated both in a radially expanded condition, and in a radially contracted condition. The treatment in a radially contracted condition is, however, preferred in that it facilitates the operations of manipulation and cleaning. Tests show that the radial contraction of a stent loaded in a radially expanded condition leads to a modest compacting of the substance loaded in therecesses 12, which acts in a synergetic way with the stabilization of the substance itself. - FIG. 2 illustrates the operation whereby (according to different modalities, described in greater detail in what follows) the substance M designed to be loaded in the
recesses 12 is applied, in the form of a powder or a paste, on the surface of thestent 1. In particular, FIG. 2 refers to an operation of application performed in a non-selective way, i.e., ensuring that the substance M not only fills therecesses 12, but covers instead the surface of thestent 1 in a practically complete way. - FIG. 3 illustrates the subsequent cleaning operation, in which the substance M in excess is removed. For example the substance M can be removed by using a localized jet of fluid coming from one or
more nozzles 17 so as to leave only thespecific dose 14 inside therecesses 12. - Non-Selective Electrostatic Loading with Powder
- A very fine powder, with a typical grain size of less than 15 micron, of drug FK 506 (tacrolimus) is laid in a thin and level layer inside a tray V. The
stent 1 is positioned on asupport 16 capable of being charged electrostatically, for example as a result of a corona treatment of the type currently performed on the printing rolls of photocopier machines (FIG. 4). Thesupport 16 is electrostatically charged, and thesupport 16/stent 1 ensemble is made to rotate (FIG. 5) at a distance of a few tenths of a millimeter from the surface of the powder that is in the tray V. The drug M is attracted over the entire surface of the support/stent ensemble and adheres in a uniform way to the stent, also filling itscavities 12. The next step is to remove the excess of drug M from the areas other than therecesses 12. For this purpose, thestent 1 still fitted on itssupport 16 is cleaned by a sequence of jets of cold water and of nitrogen under pressure shot from one ormore nozzles 17 appropriately positioned around the stent (FIG. 6). Alternatively, thestent 1 is fitted on a nozzle comprising a perforated tube and is impinged upon by a short sequence of jets of cold water, emitted under pressure from inside the stent. The jets of water are interspersed with puffs of nitrogen under pressure. The remaining residue is removed from the outer surface of the stent thanks to the rubbing of the latter against a second support, e.g., a cylinder with a compliant, i.e., soft surface. - To stabilize the drug in the sculptures (recesses)12, the stent that has been loaded is subjected to a spray of solvent effective on FK506, such as for example acetonitrile, from a distance of 15 cm, or else exposed to acetonitrile vapors in a chamber for thin-layer chromatography for 5 minutes.
- Selective Electrostatic Loading with Powder
- As in the case of the previous example, a very fine powder of the drug FK506 (tacrolimus), with the same grain size as in Example 1, is laid in a thin and level layer inside a tray
V. A roll 18 coated with photosensitive material capable of being charged electrostatically is exposed to alight source 20 capable of activating or de-activating in a selective way (from the standpoint of electrostatic charging) areas of the surface of thephotosensitive roll 18 according to a geometry corresponding to the geometry of the recesses 12 (FIG. 7). The final result is the presence, on the surface of theroll 18, of a distribution of electrostatic charges that reproduces the distribution of therecesses 12 on the surface of the stent. - Then, by passing over the bed of powder that is in the tray V, the
roll 18 carries away with itmasses 14 of drug M, the distribution and shape of which correspond to those of the recesses 12 (FIG. 8). Theroll 18 is then used (like an offset roll in a similar printing process) for transferring themasses 14 into therecesses 12 of thestent 1 mounted on the support 16 (this also usually being charged electrostatically) (FIG. 8). - The drug M is deposited on the
stent 1, which turns in an opposite direction alongside theroll 18, in areas corresponding to the sculptures or recesses 12. When all the recesses or sculptures of the stent are loaded with the drug, the next step of the process is the fixation of the substance according to the procedure already described previously (acetonitrile vapors in a thin-layer chromatography chamber for 5 minutes). - It will be appreciated that the process just described, in addition to not requiring the step of cleaning of the excess drug, lends itself also to being repeated with different substances, for example so as to fill different recesses with different drugs. In particular the operations of: (i) subjecting the
roll 18, functioning as support for transfer of the active substance M, to a charging treatment designed to obtain electrostatic charging of respective regions that are homologous with respect to therecesses 12 of the surface of thestent 1, (ii) exposing theroll 18, with the aforesaid respective electrostatically charged regions, to the active substance M that is in the tray V, ensuring that the electrostatic charge will cause transfer of the active substance onto the electrostatically charged regions of theroll 18, and (iii) exposing the roll with the active substance M, transferred onto said respective electrostatically charged regions, to the surface of thestent 1, said exposure determining the transfer of the active substance M into therecesses 12 of thestent 1, each can be repeated by employing active substances M that are each time different, with the respective electrostatically charged regions of theroll 18 chosen so that they are either identical or different for the various active substances used. - As has been mentioned previously, the presence, at least on the outer surface of the
stent 1, of a coating of biocompatible carbon material proves advantageous for the purposes of loading the stent performed according to the processes of an electrostatic type described in Examples 1 and 2. - Examples 1 and 2 set forth previously can also be implemented using a paste and not a powder. In this case, the transfer of the substance M onto the electrostatically charged areas of the
stent 1 or of theroll 18 usually presupposes an at least marginal contact and not only the close proximity between the substance M and thestent 1 or theroll 18. - Rolling on a Bed or Mat of Paste
- A mixture of drug FK506 (tacrolimus) with glycerine is prepared by amalgamating the powder of Example 1 with a few drops of glycerine. The paste thus obtained, indicated by M, has a viscosity that is hard to determine but can be estimated to have a lower limit of 100,000 to 120,000 cps.
- The paste M is then deposited and spread out over a surface P, such as for example the bottom of a tray (not illustrated), so as to form a uniform bed or mat. The
support 16 for the stent is mounted so as to be able to rotate with respect to its longitudinal axis and an axis to translate along the tray itself on a track. By means of the movement of rotation and translation, accompanied by a certain pressure, the outer surface of the stent comes into contact with the paste M, and a layer of paste P is deposited on the outer surface of the stent and fills the recesses 12 (FIG. 9). - Tests show that, at least for some ranges of viscosity and of adhesiveness of the paste (parameters that depend of course upon the nature and upon the quantity of components), the phenomenon of transfer of the paste on the
stent 1 involves, in a practically exclusive way, therecesses 12, which evidently exert a sort of action of “capture” on the paste. After having possibly removed the fractions of paste M that have remained adherent to the regions of the surface of the stent other than the recesses 12 (FIG. 10), thestent 1 itself is then removed from thesupport 16 and left to rest at room temperature (e.g., for a period not shorter than 6 hours). - To render homogeneous and intimately adherent, i.e., to stabilize, the drug-glycerine mixture on the surface of the sculptures, the stent is subsequently exposed to vapors of ethyl alcohol in a thin-layer chromatography chamber. Exposure is performed for 5 minutes at 30° C. The stent is then left to dry for 6 hours, dipped for 15 seconds in water, and again left to dry for 24 hours. In a less preferred way, the operation of removal of the fractions of paste M that remain adherent to the regions of the surface of the stent other than the
recesses 12 may possibly follow the operation of stabilization, instead of preceding it. - Rolling on a Bed or Mat of Paste
- A mixture of drug FK506 (tacrolimus) and of polycaprolactone in the form of powder (in a ratio of 6:4) is prepared by amalgamating the powder with a few drops of ethyl acetate. Also in this case, the paste thus obtained, designated by M, has a viscosity that is hard to determine but can be estimated to have a lower limit of 100,000 to 120,000 cps.
- As in the case of Example 3, the paste M is then deposited and spread out over a surface P, such as for example the bottom of a tray (not illustrated), so as to form a uniform bed or mat. Once again in a way similar to what was seen in the case of Example 3, the
support 16 for the stent is mounted so as to be able to rotate with respect to its longitudinal axis and translate along the tray itself on a track, applying to the stent a certain pressure in the direction of the bed of paste M. - Applied on the stent, mounted on the
support 16, is amask 22 consisting of a metal cylinder withslits 24 the geometry of which corresponds to the geometry (number, shape and position) of the sculptures or recesses 12 present on the outer surface of the stent (FIG. 11). The diameter of themask 22 is chosen so that, once fitted on thestent 1, themask 22 will adhere perfectly to the outer surface thereof, leaving free only the required recesses 12. Also in this case, the movement of rotation and translation of thesupport 16/stent 1/mask 24 ensemble on the tray containing the paste M enables deposition of a layer of paste M on the outer surface of themask 24 and in therecesses 12 of thestent 1 that are left free by theopenings 24 of themask 22. - At this point, the next step is the fixation of the drug-polymer mixture to the surface of the
stent 1/mask 22 ensemble, for example by putting everything in a stove at 65° C. for 15 minutes. Once cooled, thestent 1 is released from themask 22 and slid out of thesupport 16. - It will be appreciated that this technique lends itself to repetition with different masks and different substances, so as to fill different recesses with different drugs. Specifically, the process of Example 4 seen previously can be conveniently implemented, as follows: (i) applying on the stent1 a first mask 22 with first openings 24 that leave uncovered first regions or recesses 12 of the stent 1; (ii) exposing the stent 1, with the first mask applied thereto, to the bed of active substance M, so that the active substance M will coat the mask 22 and the first regions 12 left uncovered by the openings 24 of the first mask 22; (iii) removing the first mask 22 from the stent 1, which is covered with the active substance in areas corresponding to the (first) regions or recesses 12 seen previously; (iv) applying on the stent 1 a second mask 22 with second openings 24, which leave uncovered second regions 12 of the stent (these may coincide at least in part with the regions 12 already coated); (v) exposing the stent 1, with the second mask applied thereto, to a bed of further active substance M (usually different from the one seen previously), so that said further active substance will coat the second mask 22 and the second regions or recesses 12 left uncovered by the openings 24 of the second mask 22; and (vi) removing the second mask 22 from the stent 1, which has thus been loaded with different substances in regions that are different or coincide with one another, according to the needs.
- Examples 3 and 4 described previously are suited to being implemented with a bed or mat of substance M in the form of powder and not in the form of paste.
- Finally, FIG. 12 refers to the possibility of applying selectively only inside the
recesses 12,respective masses 14 of material in the form of paste. This is achieved by means of a dispensingnozzle 25 which may be brought into a position facing therecesses 12, then imparting on therecess 12 each time involved and on the nozzle 25 a relative movement that leads the nozzle to “scan” therecess 12, depositing inside it the substance M. This solution may be achieved with a high degree of precision by resorting to a numerical control machine for controlling the relative movement (usually of translation and rotation) of thesupport 16 that carries thestent 1 and of the dispensingnozzle 25. - The unexpected aspect of this solution, which is apparently very simple, lies in the fact that, contrary to the reasonable expectation of the sector, the pure and simple deposition of the substance M in the form of paste, followed by a treatment of stabilization conducted according to the criteria described previously (and, in a preferred way, by the subsequent contraction of the stent, treated in a radially expanded condition, into a radially contracted condition required, for example, for mounting on the balloon of an insertion catheter), is sufficient to ensure the firm retention of the
masses 14 inside therecesses 12. This retention occurs without any risk of dispersion, for example, in the steps of packaging, transportation, manipulation and insertion of the stent in the implantation site. - From the foregoing, it clearly emerges that the individual steps of treatment set forth with reference to the examples seen previously are freely transposable from one context of application to another among the ones previously considered. Furthermore, it is evident that the examples documented above do not exhaust the range of application, nor the variants of embodiment of the solution here described. This applies in particular to the treatments of stabilization which, as has already been mentioned previously, may envisage operations such as: (i) exposure to temperature or to thermal cycles; (ii) dipping in solvent for controlled lengths of time; (iii) exposure to solvent spray; (iv) exposure to solvent vapors; (v) selective treatment with laser beam (exposure of the recesses to laser beams); (vi) selective or integral application of a protective adhesive coating (in the form of a plug for closing the recesses); and (vii) lyophilization.
- It will likewise be appreciated that the final result achieved is the location of the active substance M on the surface of the
stent 1, in a position directly exposed to the outside, even though usually at least slightly set back in therecesses 12, without the need for providing coatings or sheaths of any sort on the surface of the stent. The surface of the stent thus remains free, with the coating of biocompatible carbon material preferably provided thereon, with consequent beneficial effects both in the implantation site of the stent, and in the steps subsequent to implantation. - Consequently, without prejudice to the principle of the invention, the details of implementation and embodiments may vary with respect to what is described and illustrated herein, without thereby departing from the scope of the present invention.
Claims (42)
1. A process for depositing an active substance on selected regions of the surface of a stent, comprising:
(i) providing the active substance in at least one form selected from the group consisting of a powder and a paste; and
(ii) depositing the active substance on the selected regions of the surface of the stent.
2. The process according to claim 1 , wherein the process comprises:
(i) coating the active substance on the selected regions and other regions of the surface of the stent; and
(ii) removing the active substance from the other regions of the surface of the stent.
3. The process according to claim 1 , wherein the active substance is applied only on the selected regions of the surface of the stent.
4. The process according to claim 3 , wherein the active substance is applied by a dispensing nozzle.
5. The process according to claim 4 , wherein a numerical control machine for fine positioning imparts on the dispensing nozzle and/or on the stent a relative movement to apply the active substance.
6. The process according to claim 2 , wherein the active substance is removed from the other regions of the surface of the stent by jets of fluid.
7. The process according to claim 2 , wherein the active substance is removed from the other regions of the surface of the stent by fitting the stent on a nozzle comprising a perforated tube and emitting jets of fluid from the nozzle and through the inside of the stent.
8. The process according to claim 6 , wherein the jets of fluid comprise jets of liquid interspersed with puffs of air.
9. The process according to claim 7 , wherein the jets of fluid comprise jets of liquid interspersed with puffs of air.
10. The process according to claim 6 , wherein the jets of fluid comprise jets of water.
11. The process according to claim 7 , wherein the jets of fluid comprise jets of water.
12. The process according to claim 6 , wherein the jets of fluid comprise puffs of nitrogen.
13. The process according to claim 7 , wherein the jets of fluid comprise puffs of nitrogen.
14. The process according to claim 2 , wherein the active substance is removed from the other regions of the surface of the stent by rubbing the surface of the stent with respect to a support.
15. The process according to claim 14 , wherein the rubbing support has a compliant surface.
16. The process according to claim 1 , wherein the process comprises:
(i) making a bed or mat of the active substance; and
(ii) exposing the stent to the bed or mat of active substance so that the active substance is transferred at least in part onto the surface of the stent.
17. The process according to claim 16 , wherein the stent is exposed to the bed or mat of active substance with application of pressure.
18. The process according to claim 16 , wherein the process comprises:
(i) exposing the stent to the bed or mat of active substance in such a way that the active substance coats a surface of the stent, the surface coated comprising the selected regions and the other regions of the surface of the stents; and
(ii) removing the active substance from the other regions of the surface of the stent.
19. The process according to claim 16 , wherein the process comprises:
(i) applying on the stent a mask with openings which leave uncovered the selected regions;
(ii) exposing the stent with the mask applied thereto to the bed or mat of active substance, so that the active substance coats the mask and the selected regions left uncovered by the openings of the mask; and
(iii) removing the mask from the stent.
20. The process according to claim 18 , wherein the process comprises:
(i) applying on the stent a first mask with first openings, which leave uncovered first selected regions of the stent;
(ii) exposing the stent, with the first mask applied thereto, to the bed or mat of active substance so that the active substance coats the mask and the first selected regions left uncovered by the first openings of the first mask;
(iii) removing the first mask from the stent;
(iv) applying on the stent a second mask with second openings which leave uncovered second selected regions of the stent;
(v) exposing the stent, with the second mask applied thereto, to a bed or mat of a second active substance, so that the second active substance will coat the second mask and the second selected regions left uncovered by the second openings of the second mask; and
(vi) removing the second mask from the stent.
21. The process according to claim 1 , wherein the process comprises:
(i) subjecting the stent to an electrostatic charging treatment designed for charging electrostatically at least the selected regions of the surface of the stent; and
(ii) exposing the stent, with at least the selected regions electrostatically charged, to the active substance, the electrostatic charge causing the transfer of the active substance onto the surface of the stent.
22. The process according to claim 21 , wherein the process comprises:
(i) subjecting the stent to an electrostatic charging treatment designed for electrostatically charging a surface comprising the selected regions and other regions of the surface of the stent, so that the electrostatic charge causes the transfer of the active substance onto a surface comprising the selected regions and other regions of the surface of the stent; and
(ii) removing the active substance from the other regions of the surface of the stent.
23. The process according to claim 21 , wherein the electrostatic charging treatment is by corona effect.
24. The process according to claim 22 , wherein the electrostatic charging treatment is by corona effect.
25. The process according to claim 1 , wherein the process comprises:
(i) providing a transfer support for the active substance;
(ii) subjecting the transfer support to a charging treatment designed for electrostatically charging respective regions of the transfer support homologous with respect to the selected regions of the surface of the stent;
(iii) exposing the transfer support, with the respective electrostatically charged regions, to the active substance, the electrostatic charge determining the transfer of the active substance onto the respective electrostatically charged regions from the transfer support; and
(iv) exposing the transfer support, with the active substance transferred onto the respective electrostatically charged regions, to the surface of the stent, the exposure determining the transfer of the active substance onto the selected regions of the stent.
26. The process according to claim 25 , wherein steps (ii), (iii), and (iv) are repeated, employing active substances that each time are different, with the respective electrostatically charged regions of the transfer support being either identical or different for the active substances used.
27. The process according to claim 21 , wherein before the electrostatic charge treatment, the stent is coated with a layer of biocompatible carbon material.
28. The process according to claim 22 , wherein before the electrostatic charge treatment, the stent is coated with a layer of biocompatible carbon material.
29. The process according to claim 25 , wherein before the electrostatic charge treatment, the stent is coated with a layer of biocompatible carbon material.
30. The process according to claim 26 , wherein before the electrostatic charge treatment, the stent is coated with a layer of biocompatible carbon material.
31. The process according to claim 1 , wherein the stent, with the active substance deposited on the selected regions of the surface of the stent, is subjected to a treatment for stabilizing the active substance.
32. The process according to claim 31 , wherein the treatment for stabilizing the active substance is chosen from the group consisting of:
(i) exposure to temperature or thermal cycles;
(ii) dipping in solvent for controlled lengths of time;
(iii) exposure to solvent spray;
(iv) exposure to solvent vapors;
(v) selective treatment with a laser;
(vi) selective or integral application of a protective adhesive coating; and
(vii) lyophilization.
33. The process according to claim 2 , wherein the stent, with the active substance deposited on the selected regions of the surface of the stent, is subjected to a treatment for stabilizing the active substance, and wherein the treatment for stabilizing the active substance is performed after the removal of the active substance from the other regions of the surface of the stent.
34. The process according to claim 1 , wherein the process is performed on the stent when the stent is in a radially contracted condition.
35. The process according to claim 1 , wherein the process is performed on the stent when the stent is in a radially expanded condition, and then subjecting the stent to radial contraction.
36. The process according to claim 1 , wherein least some of the selected regions are cavities or recesses in the surface of the stent.
37. The process according to claim 1 , wherein the active substance comprises FK506.
38. The process according to claim 1 , wherein the active substance consists essentially of FK506.
39. The process according to claim 37 , wherein the active substance consists essentially of FK506 in the form of powder with a grain size not greater than 15 micron.
40. The process according to claim 37 , wherein the active substance consists essentially of a paste with a base of FK506 with a viscosity having a value not less than 100,000 to 120,000 cps.
41. A stent loaded with at least one active substance, the stent having been made according to the process of claim 1 .
42. The process according to claim 36 , wherein the active substance deposited in the cavities or recesses is subjected to a treatment for stabilizing the active substance selected from the group consisting of:
(i) exposing the cavities or recesses that contain the active substance to a laser; and
(ii) selective or integral application of a protective adhesive coating in the form of a plug to close the cavities or recesses that contain the active substance.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/027,347 US8084076B2 (en) | 2003-02-21 | 2008-02-07 | Process for producing stents and corresponding stents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03425106.6 | 2003-02-21 | ||
EP03425106A EP1449546B1 (en) | 2003-02-21 | 2003-02-21 | A process for producing stents and corresponding stent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/027,347 Continuation US8084076B2 (en) | 2003-02-21 | 2008-02-07 | Process for producing stents and corresponding stents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040167612A1 true US20040167612A1 (en) | 2004-08-26 |
Family
ID=32731650
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/782,412 Abandoned US20040167612A1 (en) | 2003-02-21 | 2004-02-19 | Process for producing stents and corresponding stents |
US12/027,347 Active 2026-07-01 US8084076B2 (en) | 2003-02-21 | 2008-02-07 | Process for producing stents and corresponding stents |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/027,347 Active 2026-07-01 US8084076B2 (en) | 2003-02-21 | 2008-02-07 | Process for producing stents and corresponding stents |
Country Status (5)
Country | Link |
---|---|
US (2) | US20040167612A1 (en) |
EP (2) | EP2253339B1 (en) |
AT (2) | ATE485847T1 (en) |
DE (1) | DE60334676D1 (en) |
ES (1) | ES2354605T3 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070193509A1 (en) * | 2006-02-17 | 2007-08-23 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US20080114449A1 (en) * | 2004-10-08 | 2008-05-15 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US20080145400A1 (en) * | 2006-11-03 | 2008-06-19 | Jan Weber | Ion Bombardment of Medical Devices |
US20090068339A1 (en) * | 2007-09-06 | 2009-03-12 | Boston Scientific Scimed, Inc. | Endoprostheses having porous claddings prepared using metal hydrides |
US20100266780A1 (en) * | 2006-02-17 | 2010-10-21 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8066763B2 (en) | 1998-04-11 | 2011-11-29 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US8353949B2 (en) | 2006-09-14 | 2013-01-15 | Boston Scientific Scimed, Inc. | Medical devices with drug-eluting coating |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8449603B2 (en) | 2008-06-18 | 2013-05-28 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8574615B2 (en) | 2006-03-24 | 2013-11-05 | Boston Scientific Scimed, Inc. | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8900292B2 (en) | 2007-08-03 | 2014-12-02 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US8920491B2 (en) | 2008-04-22 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7550005B2 (en) | 1995-06-07 | 2009-06-23 | Cook Incorporated | Coated implantable medical device |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US7169178B1 (en) * | 2002-11-12 | 2007-01-30 | Advanced Cardiovascular Systems, Inc. | Stent with drug coating |
ITTO20040056A1 (en) * | 2004-02-05 | 2004-05-05 | Sorin Biomedica Cardio Spa | STENT FOR THE ENDOLIMINAL DELIVERY OF PRINCIPLES OR ACTIVE AGENTS |
AU2006230331B2 (en) * | 2005-03-31 | 2012-08-09 | Conor Medsystems, Inc. | Method for loading a beneficial agent into a medical device |
US7833266B2 (en) | 2007-11-28 | 2010-11-16 | Boston Scientific Scimed, Inc. | Bifurcated stent with drug wells for specific ostial, carina, and side branch treatment |
US7951193B2 (en) | 2008-07-23 | 2011-05-31 | Boston Scientific Scimed, Inc. | Drug-eluting stent |
EP2359876A1 (en) * | 2010-02-12 | 2011-08-24 | Aesculap AG | Medical device comprising a porous article of ePTFE exhibiting improved cellular tissue ingrowth |
WO2012027386A2 (en) * | 2010-08-23 | 2012-03-01 | Imtec Biomedical Inc. | A method and system of devices for permanent access to the circulatory system for chronic hemodialysis |
IT201900003579A1 (en) | 2019-03-12 | 2020-09-12 | Alvimedica Tibbi Ueruenler Sanayi Ve Dis Ticaret A S | STENT FOR CORONARY OSTIUM |
Citations (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5084151A (en) * | 1985-11-26 | 1992-01-28 | Sorin Biomedica S.P.A. | Method and apparatus for forming prosthetic device having a biocompatible carbon film thereon |
US5133845A (en) * | 1986-12-12 | 1992-07-28 | Sorin Biomedica, S.P.A. | Method for making prosthesis of polymeric material coated with biocompatible carbon |
US5370684A (en) * | 1986-12-12 | 1994-12-06 | Sorin Biomedica S.P.A. | Prosthesis of polymeric material coated with biocompatible carbon |
US5387247A (en) * | 1983-10-25 | 1995-02-07 | Sorin Biomedia S.P.A. | Prosthetic device having a biocompatible carbon film thereon and a method of and apparatus for forming such device |
US5423886A (en) * | 1987-05-11 | 1995-06-13 | Sorin Biomedica S.P.A. | Cyclically deformable haemocompatible and biocompatible devices coated with biocompatible carbonaceous material |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US5925402A (en) * | 1998-07-15 | 1999-07-20 | Morton International, Inc. | Method of forming a hidden identification using powder coating |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6156373A (en) * | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6254632B1 (en) * | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6273908B1 (en) * | 1997-10-24 | 2001-08-14 | Robert Ndondo-Lay | Stents |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6325821B1 (en) * | 1997-04-29 | 2001-12-04 | Sorin Biomedica Cardio S.P.A. | Stent for angioplasty |
US6364856B1 (en) * | 1998-04-14 | 2002-04-02 | Boston Scientific Corporation | Medical device with sponge coating for controlled drug release |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6451050B1 (en) * | 2000-04-28 | 2002-09-17 | Cardiovasc, Inc. | Stent graft and method |
US20030134052A1 (en) * | 2000-06-29 | 2003-07-17 | Dave Vipul Bhupendra | Electrostatic impregnation of powders on substrates |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
US6620194B2 (en) * | 1995-04-19 | 2003-09-16 | Boston Scientific Scimed, Inc. | Drug coating with topcoat |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
US6627246B2 (en) * | 2000-05-16 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating stents and other medical devices using super-critical carbon dioxide |
US6638302B1 (en) * | 1996-12-30 | 2003-10-28 | Sorin Biomedica Cardio S.P.A. | Stent for angioplasty and associated production process |
US6652581B1 (en) * | 1998-07-07 | 2003-11-25 | Boston Scientific Scimed, Inc. | Medical device with porous surface for controlled drug release and method of making the same |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US6743463B2 (en) * | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US6743643B2 (en) * | 2001-11-29 | 2004-06-01 | Symetrix Corporation | Stacked memory cell having diffusion barriers |
US6746773B2 (en) * | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
US20040202773A1 (en) * | 2002-11-07 | 2004-10-14 | Donald Verlee | Method of loading beneficial agent to a prosthesis by fluid-jet application |
US6833004B2 (en) * | 2001-07-06 | 2004-12-21 | Terumo Kabushiki Kaisha | Stent |
US6852122B2 (en) * | 2003-01-23 | 2005-02-08 | Cordis Corporation | Coated endovascular AAA device |
US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US6890463B2 (en) * | 2000-10-03 | 2005-05-10 | Atrium Medical Corporation | Method for treating expandable polymer materials |
US6893859B2 (en) * | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6896965B1 (en) * | 2002-11-12 | 2005-05-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices |
US6908622B2 (en) * | 2001-09-24 | 2005-06-21 | Boston Scientific Scimed, Inc. | Optimized dosing for drug coated stents |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3727577A (en) * | 1970-07-24 | 1973-04-17 | Usm Corp | Machines for coating sheet material |
CA2086642C (en) | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
US5609629A (en) | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
DE69738786D1 (en) | 1996-05-08 | 2008-07-31 | Sorin Biomedica Cardio Srl | A stent for angioplasty |
US5797887A (en) | 1996-08-27 | 1998-08-25 | Novovasc Llc | Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosyl-containing organo-metallic compound which releases nitric oxide from the coating to mediate platelet aggregation |
US6451049B2 (en) | 1998-04-29 | 2002-09-17 | Sorin Biomedica Cardio, S.P.A. | Stents for angioplasty |
IT1293690B1 (en) | 1997-08-08 | 1999-03-08 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT, PARTICULARLY FOR THE TREATMENT OF AORTO-HOSPITAL AND HOSPITAL INJURIES. |
IT1293691B1 (en) | 1997-08-08 | 1999-03-08 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT, IN PARTICULAR FOR THE TREATMENT OF POTS PRESENTING BIFURCATIONS. |
BR9916636A (en) * | 1998-12-31 | 2001-09-18 | Angiotech Pharm Inc | Stent grafts with bioactive coatings |
US6120847A (en) * | 1999-01-08 | 2000-09-19 | Scimed Life Systems, Inc. | Surface treatment method for stent coating |
US6364903B2 (en) * | 1999-03-19 | 2002-04-02 | Meadox Medicals, Inc. | Polymer coated stent |
IT1307263B1 (en) | 1999-08-05 | 2001-10-30 | Sorin Biomedica Cardio Spa | ANGIOPLASTIC STENT WITH RESTENOSIS ANTAGONIST ACTION, RELATED KIT AND COMPONENTS. |
EP1103234B1 (en) | 1999-11-23 | 2007-01-24 | Sorin Biomedica Cardio S.R.L. | Method for conveying radioactive agents on angioplasty stents and kit |
WO2001082833A2 (en) * | 2000-04-28 | 2001-11-08 | Cardiovasc, Inc. | Stent graft assembly and method |
US6395326B1 (en) * | 2000-05-31 | 2002-05-28 | Advanced Cardiovascular Systems, Inc. | Apparatus and method for depositing a coating onto a surface of a prosthesis |
IT1320232B1 (en) | 2000-07-11 | 2003-11-26 | Sorin Biomedica Cardio Spa | PROCEDURE FOR COUPLING AN ANGIOPLASTIC STENT WITH AN ADDITIONAL INSERTION ELEMENT AND SO ACCOMPANYING FORMAT. |
CN1225292C (en) | 2000-09-29 | 2005-11-02 | 伊西康公司 | Coatings for medical devices |
AU1129902A (en) | 2000-09-29 | 2002-04-08 | Cordis Corp | Coated medical devices |
EP1212986A1 (en) | 2000-12-08 | 2002-06-12 | SORIN BIOMEDICA CARDIO S.p.A. | An angioplasty stent and manufacturing method thereof |
US20020103526A1 (en) | 2000-12-15 | 2002-08-01 | Tom Steinke | Protective coating for stent |
AU2002249826A1 (en) | 2000-12-22 | 2002-07-30 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
DE50210591D1 (en) | 2001-02-16 | 2007-09-13 | Abbott Lab Vascular Entpr Ltd | IMPLANTS WITH FK506 FOR RESTENOSIS TREATMENT AND PROPHYLAXIS |
EP1254673B1 (en) | 2001-05-02 | 2005-11-09 | InFlow Dynamics, Inc. | Immuno-tolerant stent with surface microstructure |
US7105199B2 (en) * | 2001-05-11 | 2006-09-12 | Exogenesis Corporation | Methods of adhering drugs to the surface of medical devices through ion beam surface modification |
US7651695B2 (en) * | 2001-05-18 | 2010-01-26 | Advanced Cardiovascular Systems, Inc. | Medicated stents for the treatment of vascular disease |
DE60120955T3 (en) | 2001-07-20 | 2015-06-25 | Cid S.P.A. | stent |
US7232635B2 (en) * | 2002-02-04 | 2007-06-19 | Konica Corporation | Image forming method, image forming apparatus, and processing cartridge |
US20040059409A1 (en) * | 2002-09-24 | 2004-03-25 | Stenzel Eric B. | Method of applying coatings to a medical device |
-
2003
- 2003-02-21 EP EP10174501A patent/EP2253339B1/en not_active Expired - Lifetime
- 2003-02-21 ES ES03425106T patent/ES2354605T3/en not_active Expired - Lifetime
- 2003-02-21 EP EP03425106A patent/EP1449546B1/en not_active Expired - Lifetime
- 2003-02-21 DE DE60334676T patent/DE60334676D1/en not_active Expired - Lifetime
- 2003-02-21 AT AT03425106T patent/ATE485847T1/en not_active IP Right Cessation
- 2003-02-21 AT AT10174501T patent/ATE538820T1/en active
-
2004
- 2004-02-19 US US10/782,412 patent/US20040167612A1/en not_active Abandoned
-
2008
- 2008-02-07 US US12/027,347 patent/US8084076B2/en active Active
Patent Citations (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5387247A (en) * | 1983-10-25 | 1995-02-07 | Sorin Biomedia S.P.A. | Prosthetic device having a biocompatible carbon film thereon and a method of and apparatus for forming such device |
US5084151A (en) * | 1985-11-26 | 1992-01-28 | Sorin Biomedica S.P.A. | Method and apparatus for forming prosthetic device having a biocompatible carbon film thereon |
US5370684A (en) * | 1986-12-12 | 1994-12-06 | Sorin Biomedica S.P.A. | Prosthesis of polymeric material coated with biocompatible carbon |
US5133845A (en) * | 1986-12-12 | 1992-07-28 | Sorin Biomedica, S.P.A. | Method for making prosthesis of polymeric material coated with biocompatible carbon |
US5423886A (en) * | 1987-05-11 | 1995-06-13 | Sorin Biomedica S.P.A. | Cyclically deformable haemocompatible and biocompatible devices coated with biocompatible carbonaceous material |
US6620194B2 (en) * | 1995-04-19 | 2003-09-16 | Boston Scientific Scimed, Inc. | Drug coating with topcoat |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5837313A (en) * | 1995-04-19 | 1998-11-17 | Schneider (Usa) Inc | Drug release stent coating process |
US6358556B1 (en) * | 1995-04-19 | 2002-03-19 | Boston Scientific Corporation | Drug release stent coating |
US6638302B1 (en) * | 1996-12-30 | 2003-10-28 | Sorin Biomedica Cardio S.P.A. | Stent for angioplasty and associated production process |
US6273913B1 (en) * | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6325821B1 (en) * | 1997-04-29 | 2001-12-04 | Sorin Biomedica Cardio S.P.A. | Stent for angioplasty |
US6670398B2 (en) * | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
US6884429B2 (en) * | 1997-09-05 | 2005-04-26 | Isotechnika International Inc. | Medical devices incorporating deuterated rapamycin for controlled delivery thereof |
US6273908B1 (en) * | 1997-10-24 | 2001-08-14 | Robert Ndondo-Lay | Stents |
US6364856B1 (en) * | 1998-04-14 | 2002-04-02 | Boston Scientific Corporation | Medical device with sponge coating for controlled drug release |
US6153252A (en) * | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
US6652581B1 (en) * | 1998-07-07 | 2003-11-25 | Boston Scientific Scimed, Inc. | Medical device with porous surface for controlled drug release and method of making the same |
US5925402A (en) * | 1998-07-15 | 1999-07-20 | Morton International, Inc. | Method of forming a hidden identification using powder coating |
US6890546B2 (en) * | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
US6368658B1 (en) * | 1999-04-19 | 2002-04-09 | Scimed Life Systems, Inc. | Coating medical devices using air suspension |
US6156373A (en) * | 1999-05-03 | 2000-12-05 | Scimed Life Systems, Inc. | Medical device coating methods and devices |
US6451050B1 (en) * | 2000-04-28 | 2002-09-17 | Cardiovasc, Inc. | Stent graft and method |
US6776796B2 (en) * | 2000-05-12 | 2004-08-17 | Cordis Corportation | Antiinflammatory drug and delivery device |
US6627246B2 (en) * | 2000-05-16 | 2003-09-30 | Ortho-Mcneil Pharmaceutical, Inc. | Process for coating stents and other medical devices using super-critical carbon dioxide |
US20030134052A1 (en) * | 2000-06-29 | 2003-07-17 | Dave Vipul Bhupendra | Electrostatic impregnation of powders on substrates |
US6254632B1 (en) * | 2000-09-28 | 2001-07-03 | Advanced Cardiovascular Systems, Inc. | Implantable medical device having protruding surface structures for drug delivery and cover attachment |
US6746773B2 (en) * | 2000-09-29 | 2004-06-08 | Ethicon, Inc. | Coatings for medical devices |
US6890463B2 (en) * | 2000-10-03 | 2005-05-10 | Atrium Medical Corporation | Method for treating expandable polymer materials |
US6893859B2 (en) * | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
US6787179B2 (en) * | 2001-06-29 | 2004-09-07 | Ethicon, Inc. | Sterilization of bioactive coatings |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US6833004B2 (en) * | 2001-07-06 | 2004-12-21 | Terumo Kabushiki Kaisha | Stent |
US6908622B2 (en) * | 2001-09-24 | 2005-06-21 | Boston Scientific Scimed, Inc. | Optimized dosing for drug coated stents |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
US6743643B2 (en) * | 2001-11-29 | 2004-06-01 | Symetrix Corporation | Stacked memory cell having diffusion barriers |
US6861088B2 (en) * | 2002-03-28 | 2005-03-01 | Boston Scientific Scimed, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US6743463B2 (en) * | 2002-03-28 | 2004-06-01 | Scimed Life Systems, Inc. | Method for spray-coating a medical device having a tubular wall such as a stent |
US20040202773A1 (en) * | 2002-11-07 | 2004-10-14 | Donald Verlee | Method of loading beneficial agent to a prosthesis by fluid-jet application |
US6896965B1 (en) * | 2002-11-12 | 2005-05-24 | Advanced Cardiovascular Systems, Inc. | Rate limiting barriers for implantable devices |
US6852122B2 (en) * | 2003-01-23 | 2005-02-08 | Cordis Corporation | Coated endovascular AAA device |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8066763B2 (en) | 1998-04-11 | 2011-11-29 | Boston Scientific Scimed, Inc. | Drug-releasing stent with ceramic-containing layer |
US8303643B2 (en) | 2001-06-27 | 2012-11-06 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
US20080114449A1 (en) * | 2004-10-08 | 2008-05-15 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US7749264B2 (en) * | 2004-10-08 | 2010-07-06 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20070193509A1 (en) * | 2006-02-17 | 2007-08-23 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US20100266780A1 (en) * | 2006-02-17 | 2010-10-21 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US7836847B2 (en) | 2006-02-17 | 2010-11-23 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US7981479B2 (en) | 2006-02-17 | 2011-07-19 | Howmedica Osteonics Corp. | Multi-station rotation system for use in spray operations |
US8574615B2 (en) | 2006-03-24 | 2013-11-05 | Boston Scientific Scimed, Inc. | Medical devices having nanoporous coatings for controlled therapeutic agent delivery |
US8187620B2 (en) | 2006-03-27 | 2012-05-29 | Boston Scientific Scimed, Inc. | Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8815275B2 (en) | 2006-06-28 | 2014-08-26 | Boston Scientific Scimed, Inc. | Coatings for medical devices comprising a therapeutic agent and a metallic material |
US8771343B2 (en) | 2006-06-29 | 2014-07-08 | Boston Scientific Scimed, Inc. | Medical devices with selective titanium oxide coatings |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US8353949B2 (en) | 2006-09-14 | 2013-01-15 | Boston Scientific Scimed, Inc. | Medical devices with drug-eluting coating |
US8057534B2 (en) | 2006-09-15 | 2011-11-15 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8808726B2 (en) | 2006-09-15 | 2014-08-19 | Boston Scientific Scimed. Inc. | Bioerodible endoprostheses and methods of making the same |
US8128689B2 (en) | 2006-09-15 | 2012-03-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
US8052744B2 (en) | 2006-09-15 | 2011-11-08 | Boston Scientific Scimed, Inc. | Medical devices and methods of making the same |
US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
US20080145400A1 (en) * | 2006-11-03 | 2008-06-19 | Jan Weber | Ion Bombardment of Medical Devices |
US7981150B2 (en) | 2006-11-09 | 2011-07-19 | Boston Scientific Scimed, Inc. | Endoprosthesis with coatings |
US8080055B2 (en) | 2006-12-28 | 2011-12-20 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8715339B2 (en) | 2006-12-28 | 2014-05-06 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8431149B2 (en) | 2007-03-01 | 2013-04-30 | Boston Scientific Scimed, Inc. | Coated medical devices for abluminal drug delivery |
US8070797B2 (en) | 2007-03-01 | 2011-12-06 | Boston Scientific Scimed, Inc. | Medical device with a porous surface for delivery of a therapeutic agent |
US8067054B2 (en) | 2007-04-05 | 2011-11-29 | Boston Scientific Scimed, Inc. | Stents with ceramic drug reservoir layer and methods of making and using the same |
US7976915B2 (en) | 2007-05-23 | 2011-07-12 | Boston Scientific Scimed, Inc. | Endoprosthesis with select ceramic morphology |
US7942926B2 (en) | 2007-07-11 | 2011-05-17 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US8002823B2 (en) | 2007-07-11 | 2011-08-23 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US9284409B2 (en) | 2007-07-19 | 2016-03-15 | Boston Scientific Scimed, Inc. | Endoprosthesis having a non-fouling surface |
US8815273B2 (en) | 2007-07-27 | 2014-08-26 | Boston Scientific Scimed, Inc. | Drug eluting medical devices having porous layers |
US7931683B2 (en) | 2007-07-27 | 2011-04-26 | Boston Scientific Scimed, Inc. | Articles having ceramic coated surfaces |
US8221822B2 (en) | 2007-07-31 | 2012-07-17 | Boston Scientific Scimed, Inc. | Medical device coating by laser cladding |
US8900292B2 (en) | 2007-08-03 | 2014-12-02 | Boston Scientific Scimed, Inc. | Coating for medical device having increased surface area |
US20090068339A1 (en) * | 2007-09-06 | 2009-03-12 | Boston Scientific Scimed, Inc. | Endoprostheses having porous claddings prepared using metal hydrides |
US7883736B2 (en) | 2007-09-06 | 2011-02-08 | Boston Scientific Scimed, Inc. | Endoprostheses having porous claddings prepared using metal hydrides |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
US8029554B2 (en) | 2007-11-02 | 2011-10-04 | Boston Scientific Scimed, Inc. | Stent with embedded material |
US8216632B2 (en) | 2007-11-02 | 2012-07-10 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7938855B2 (en) | 2007-11-02 | 2011-05-10 | Boston Scientific Scimed, Inc. | Deformable underlayer for stent |
US8920491B2 (en) | 2008-04-22 | 2014-12-30 | Boston Scientific Scimed, Inc. | Medical devices having a coating of inorganic material |
US8932346B2 (en) | 2008-04-24 | 2015-01-13 | Boston Scientific Scimed, Inc. | Medical devices having inorganic particle layers |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8449603B2 (en) | 2008-06-18 | 2013-05-28 | Boston Scientific Scimed, Inc. | Endoprosthesis coating |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8231980B2 (en) | 2008-12-03 | 2012-07-31 | Boston Scientific Scimed, Inc. | Medical implants including iridium oxide |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8071156B2 (en) | 2009-03-04 | 2011-12-06 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8287937B2 (en) | 2009-04-24 | 2012-10-16 | Boston Scientific Scimed, Inc. | Endoprosthese |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
Also Published As
Publication number | Publication date |
---|---|
ATE485847T1 (en) | 2010-11-15 |
EP2253339B1 (en) | 2011-12-28 |
EP2253339A1 (en) | 2010-11-24 |
ES2354605T3 (en) | 2011-03-16 |
US20080140186A1 (en) | 2008-06-12 |
EP1449546B1 (en) | 2010-10-27 |
US8084076B2 (en) | 2011-12-27 |
DE60334676D1 (en) | 2010-12-09 |
ATE538820T1 (en) | 2012-01-15 |
EP1449546A1 (en) | 2004-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8084076B2 (en) | Process for producing stents and corresponding stents | |
EP1561436B1 (en) | A stent for endoluminal delivery of active principles or agents | |
JP4044190B2 (en) | Method for producing drug-releasing coating | |
EP1569762B1 (en) | Stent with intermittent coating | |
US6506437B1 (en) | Methods of coating an implantable device having depots formed in a surface thereof | |
US6287628B1 (en) | Porous prosthesis and a method of depositing substances into the pores | |
US20110066228A1 (en) | Carrier and kit for intraluminal delivery of active principles or agents | |
JP4949227B2 (en) | Multidrug delivery from balloons and prostheses | |
US6379381B1 (en) | Porous prosthesis and a method of depositing substances into the pores | |
US7563324B1 (en) | System and method for coating an implantable medical device | |
EP1214108B1 (en) | A porous prosthesis and a method of depositing substances into the pores | |
US20070173923A1 (en) | Drug reservoir stent | |
EP1781203B1 (en) | Methods and systems for loading an implantable medical device with beneficial agent | |
US7824729B2 (en) | Methods for coating an implantable device | |
US20120316496A1 (en) | Use of compositions to coat catheter balloons and coated catheter balloons | |
US20040249444A1 (en) | Method and system for created a textured surface on an implantable medical device | |
JP2006500118A (en) | Method and apparatus for filling an expandable medical device with a beneficial agent | |
WO2002034311A2 (en) | Selective coating of medical devices | |
JP2009513181A (en) | Device having a treated surface structure with a coating for controlled drug release | |
CA2668130A1 (en) | Stents with drug eluting coatings | |
US20110274732A1 (en) | Medical device loaded with formulation for targeted delivery of biologically active material/s and method of manufacture thereof | |
ES2379451T3 (en) | Stent and corresponding stent manufacturing procedure | |
JP2008534142A (en) | System and method for loading a beneficial substance into a medical device |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SORIN BIOMEDICA CARDIO S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRIGNANI, ANDREA;CURCIO, MARIA;CASSOLARO, VINCENZO;REEL/FRAME:015021/0248 Effective date: 20040217 |
|
AS | Assignment |
Owner name: SORIN BIOMEDICA CARDIO S.R.L., ITALY Free format text: CHANGE OF NAME;ASSIGNOR:SORIN BIOMEDICA CARDIO S.P.A.;REEL/FRAME:020480/0334 Effective date: 20040803 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |